The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that therapeutic responses may be improved via its modulation (13, 14)”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [14]
In the citing paper
“The P-ESC was considered representative of baseline microbiome data due to observations that the microbiome of patients treated with anti-PD-1, unlike anti-CTLA-4 or chemotherapy, is stable early after therapy initiation17–19.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [19]
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [26]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 2×
“Finally, monoassociation of tumor-bearing GF mice with SFB, which promotes Th17 cell differentiation in the LP (1, 13, 14) also had a detrimental impact on the tumor growthinhibitory effect of CTX (Fig.”
BackgroundImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Some antineoplastic agents mediate part of their anticancer activity by stimulating anticancer immune responses (6).”
BackgroundSelf-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“S6A) and is required for the therapeutic success of anticancer chemotherapies in several tumor models (19).”
BackgroundSelf-citationInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Self-citation
Research works printed but not linked: 1
- 10.1073/pnas.1113744109 · DOI · Paper page
Cited by
Items 701–800 of 1,012
A potential therapeutic strategy for prostatic disease by targeting the oral microbiome
Fang, C., Wu, L., Zhu, C., Xie, W., Hu, H., & Zeng, X. (2020) · Medicinal Research Reviews · doi:10.1002/med.21778 · Cited by 51
Lv, L., Mu, D., Du, Y., Ren, Y., & Jiang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694344 · Cited by 51
Small molecules in the big picture of gut microbiome-host cross-talk
Ma, Y., Liu, X., & Wang, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104085 · Cited by 53
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
Zhang, Y., Cui, Q., Xu, M., Liu, D., Yao, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901772 · Cited by 51
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 48
Interaction between microbiota and immunity and its implication in colorectal cancer
Xing, C., Du, Y., Duan, T., Nim, K., Chu, J., Wang, H. Y., & Wang, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963819 · Cited by 51
Enterococci facilitate polymicrobial infections
Xu, W., Fang, Y., & Zhu, K. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.07.010 · Cited by 48
Microbiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
Lu, S., Zuo, T., Zhang, N., Shi, H., Liu, F., Wu, J., Wang, Y., Xue, C., & Tang, Q. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.11.017 · Cited by 48
Hahn, A. W., Froerer, C., VanAlstine, S., Rathi, N., Bailey, E. B., Stenehjem, D. D., & Agarwal, N. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.05.001 · Cited by 46
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Implications of the Human Gut–Brain and Gut–Cancer Axes for Future Nanomedicine
Javed, I., Cui, X., Wang, X., Mortimer, M., Andrikopoulos, N. K., Li, Y., Davis, T. P., Zhao, Y., Ke, P. C., & Chen, C. (2020) · ACS Nano · doi:10.1021/acsnano.0c07258 · Cited by 48
The role of the microbiome in drug resistance in gastrointestinal cancers
Garajová, I., Balsano, R., Wang, H., Leonardi, F., Giovannetti, E., Deng, D., & Peters, G. J. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1844007 · Cited by 50
Gut microbiota targeted nanomedicine for cancer therapy: Challenges and future considerations
Rajoka, M. S. R., Mehwish, H. M., Xiong, Y., Song, X., Hussain, N., Zhu, Q., & He, Z. (2020) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.10.036 · Cited by 47
Li, Y., Liu, H., Qi, H., Tang, W., Zhang, C., Liu, Z., Liu, Y., Wei, X., Kong, Z., Jia, S., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111909 · Cited by 47
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?
Guo, H., Zhao, L., Zhu, J., Chen, P., Wang, H., Jiang, M., Liu, X., Sun, H., Zhao, W., Zheng, Z., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.025 · Cited by 50
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
Self-citationThe triple interactions between gut microbiota, mycobiota and host immunity
Yang, J., Yang, H., & Li, Y. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2094888 · Cited by 49
Aarnoutse, R., Ziemons, J., Hillege, L. E., de Vos-Geelen, J., de Boer, M., Bisschop, S. M. P., Vriens, B. E. P. J., Vincent, J., van de Wouw, A. J., Le, G. N., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00455-5 · Cited by 43
Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
de Medeiros, M. C., The, S., Bellile, E. L., Russo, N., Schmitd, L. B., Danella, E. B., Singh, P. A., Banerjee, R., Bassis, C. M., Murphy, G. R., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01677-w · Cited by 50
Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., et al. (2023) · Cancers · doi:10.3390/cancers16010047 · Cited by 48
Chen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00818-3 · Cited by 51
Belcheva, A., Irrazabal, T., & Martin, A. (2015) · BioEssays · doi:10.1002/bies.201400204 · Cited by 45
Bingula, R., Filaire, M., Radosevic‐Robin, N., Berthon, J., Bernalier‐Donadille, A., Vasson, M., Thivat, É., Kwiatkowski, F., & Filaire, E. (2018) · Medicine · doi:10.1097/md.0000000000013676 · Cited by 49
Li, Y., Ye, Z., Zhu, J., Fang, S., Meng, L., & Zhou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844335 · Cited by 45
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 48
Tabrizi, E., Tabrizi, F. P. F., Khaled, G. M., Sestito, M. P., Jamie, S., & Boone, B. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434771 · Cited by 46
Wekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 46
Functional Classification of the Gut Microbiota: The Key to Cracking the Microbiota Composition Code
Rosen, C. E., & Palm, N. W. (2017) · BioEssays · doi:10.1002/bies.201700032 · Cited by 47
von Frieling, J., Fink, C., Hamm, J., Klischies, K., Förster, M., Bosch, T. C. G., Roeder, T., Rosenstiel, P. C., & Sommer, F. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02020 · Cited by 49
Opportunities and Challenges of the Human Microbiome in Ovarian Cancer
Cheng, H., Wang, Z., Cui, L., Wen, Y. L., Chen, X., Gong, F., & Yi, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00163 · Cited by 46
Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations
Chen, Z., Zhang, S., Dong, S., Xu, H., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844401 · Cited by 44
Dey, P., & Chaudhuri, S. R. (2022) · Biology · doi:10.3390/biology11050757 · Cited by 46
The conundrum of breast cancer and microbiome - A comprehensive review of the current evidence
Papakonstantinou, A., Nuciforo, P. G., Borrell, M., Zamora, E., Pimentel, I., Saura, C., & Oliveira, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102470 · Cited by 51
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients
Eaton, S. E., Kaczmarek, J., Mahmood, D., McDiarmid, A. M., Norarfan, A. N., Scott, E. G., Then, C. K., Tsui, H. Y., & Kiltie, A. E. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01980-7 · Cited by 45
Dalmasso, G., Cougnoux, A., Faïs, T., Bonnin, V., Mottet-Auselo, B., Nguyen, H. T. T., Sauvanet, P., Barnich, N., Jary, M., Pezet, D., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2310215 · Cited by 45
Microbiome sequencing: challenges and opportunities for molecular medicine
Clavel, T., Lagkouvardos, I., & Hiergeist, A. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1184574 · Cited by 45
Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders
Rajani, C., & Jia, W. P. (2018) · Clinical Science · doi:10.1042/cs20171328 · Cited by 45
Iida, N., Mizukoshi, E., Yamashita, T., Terashima, T., Arai, K., Seishima, J., & Kaneko, S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32339 · Cited by 46
Shi, F., Qiu, X., Nie, L., Hu, L., Babu, V. S., Lin, Q., Zhang, Y., Chen, L., Li, J., Lin, L., et al. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.07.049 · Cited by 44
Intratumoral levels and prognostic significance of Fusobacterium nucleatum in cervical carcinoma
Huang, S., Chen, J., Lian, L.-Y., Cai, H., Zeng, H.-S., Zheng, M., & Liu, M. (2020) · Aging · doi:10.18632/aging.104188 · Cited by 53
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation
Čierniková, S., Kasperová, B. J., Drgoňa, Ľ., Smolková, B., Števurková, V., & Mego, M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100790 · Cited by 44
Fuentes‐Chust, C., Parolo, C., Rosati, G., Rivas, L., Perez‐Toralla, K., Simon, S., de Lecuona, I., Junot, C., Trebicka, J., & Merkoçi, A. (2021) · Advanced Materials · doi:10.1002/adma.202006104 · Cited by 47
Chen, L., Zhai, Y., Wang, Y., Fearon, E. R., Núñez, G., Inohara, N., & Cho, K. R. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0106 · Cited by 45
Bacteriophage-mediated modulation of microbiota for diseases treatment
Zhang, Y., Li, C., & Zhang, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113856 · Cited by 46
An update on drug–drug interactions associated with proton pump inhibitors
Ghezala, I. B., Luu, M., & Bardou, M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2098107 · Cited by 48
Cancer Immunity: Lessons From Infectious Diseases
Trinchieri, G. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv070 · Cited by 46
For Host's Sake: The Pluses of Parasite Preservation
Spencer, H. G., & Zuk, M. (2016) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2016.02.021 · Cited by 44
The intestinal microbiome influences checkpoint blockade
Sears, C. L., & Pardoll, D. M. (2018) · Nature Medicine · doi:10.1038/nm.4511 · Cited by 43
Tannic Acid-Modified Silver Nanoparticles for Antibacterial and Anticancer Applications
Ha, W., Yang, J., & Shi, Y. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c01291 · Cited by 43
The Effect of Mushroom Dietary Fiber on the Gut Microbiota and Related Health Benefits: A Review
Yu, C., Dong, Q., Chen, M., Zhao, R., Zha, L., Zhao, Y., Zhang, M., Zhang, B., & Ma, A. (2023) · Journal of Fungi · doi:10.3390/jof9101028 · Cited by 47
Chen, Q., He, Z., Liu, W., Lin, X., Wu, J., Li, H., & Lin, J. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500383 · Cited by 44
Mitsuhashi, A., & Okuma, Y. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1827-7 · Cited by 45
Is it true that gut microbiota is considered as panacea in cancer therapy?
Farrokhi, A. S., Darabi, N., Yousefi, B., Askandar, R. H., Shariati, M., & Eslami, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28333 · Cited by 44
Chambers, L., Kuznicki, M. L., Yao, M., Chichura, A. M., Gruner, M., Reizes, O., Debernardo, R. L., Rose, P. G., Michener, C. M., & Vargas, R. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.010 · Cited by 43
Guo, C., Cui, Q., Cheng, J., Chen, J., Zhao, Z., Guo, R., Dai, X., Wei, Z., & Li, W. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104424 · Cited by 44
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma
Li, X., Wu, B., Jiang, Y., Li, J., Wang, X., Ma, C., Li, Y., Yao, J., Jin, X., & Li, Z. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s298261 · Cited by 43
Wu, Z., Zhang, S., Li, L., Huang, Z., Huang, D., & Hu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887383 · Cited by 44
Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I., Gabrielli, G., Nasta, S. D., Porazzi, P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011492 · Cited by 44
Microbiome and pancreatic cancer: time to think about chemotherapy
de Castilhos, J., Tillmanns, K., Blessing, J., Larano, A., Borisov, V., & Stein‐Thoeringer, C. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2374596 · Cited by 42
How human microbiome talks to health and disease
Cong, J., & Zhang, X. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3263-1 · Cited by 52
The promise and challenge of cancer microbiome research
Manzoor, S. S., Doedens, A. M., & Burns, M. B. (2020) · Genome biology · doi:10.1186/s13059-020-02037-9 · Cited by 43
Human microbiome and prostate cancer development: current insights into the prevention and treatment
Moghadam, S. O., & Momeni, S. A. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0731-7 · Cited by 43
Microbiota and cancer: current understanding and mechanistic implications
Khan, A. A., Sirsat, A., Singh, H., & Cash, P. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02690-x · Cited by 45
Yin, L., Huang, G., Khan, I., Su, L., Xia, W., Law, B. Y. K., Wong, V. K. W., Wu, Q., Wang, J., Leong, W. K., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00667-8 · Cited by 43
Jenkins, S. V., Robeson, M. S., Griffin, R. J., Quick, C. M., Siegel, E. R., Cannon, M. J., Vang, K. B., & Dings, R. P. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4108 · Cited by 41
Xia, W., Liu, B., Tang, S., Yasir, M., & Khan, I. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.875513 · Cited by 41
Vaginal microbiomes and ovarian cancer: a review.
Xu, J., Peng, J.-J., Yang, W., Fu, K., & Zhang, Y. (2020) · PubMed Central · Cited by 52
Daillère, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinská, E., De Vries, I. J. M., Naccarati, A. G., Zitvogel, V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774298 · Cited by 38
Self-citationThe role of gut microbiota in tumorigenesis and treatment
Xu, J., Liu, M.-T., Tao, T., Zhu, X. M., & Fei, F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111444 · Cited by 45
Common themes in antimicrobial and anticancer drug resistance
Chifiriuc, M. C., Filip, R., Constantin, M., Pîrcălăbioru, G. G., Bleoţu, C., Burlibaşa, L., Ionica, E., Corcionivoschi, N., & Mihăescu, G. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.960693 · Cited by 41
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“For example, cyclophosphamide induces gut transmucosal translocation of Enterococcus hirae to secondary lymphoid organs with consequent stimulation of Th17 responses and IFN-producing CD8þ T-effector cells in sarcoma models and lung adenocarcinoma models (14, 15).”
BackgroundCross-reactivity between microbial and tumor antigens
Zitvogel, L., & Kroemer, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102171 · Cited by 40
Self-citationThe gut microbiome and melanoma: A review
Makaranka, S., Scutt, F., Frixou, M., Wensley, K. E., Sharma, R., & Greenhowe, J. (2022) · Experimental Dermatology · doi:10.1111/exd.14639 · Cited by 43
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 42
Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy
Deng, Y., Hou, X., Wang, H., Du, H., & Liu, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17050604 · Cited by 40
Gut microbiota interact with breast cancer therapeutics to modulate efficacy
Arnone, A. A., Ansley, K. C., Heeke, A. L., Howard-McNatt, M. M., & Cook, K. L. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00185-0 · Cited by 44
Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
Liu, Q., Yang, Y., Tan, X., Tao, Z., Adah, D., Yu, S., Lu, J., Zhao, S., Qin, L., Qin, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15806 · Cited by 42
The influence of the commensal microbiota on distal tumor-promoting inflammation
Rosean, C. M. B., & Rutkowski, M. R. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.06.002 · Cited by 41
How gut microbes are joining the fight against cancer
Guglielmi, G. (2018) · Nature · doi:10.1038/d41586-018-05208-8 · Cited by 47
Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 41
Human Gut Microbiome and Liver Diseases: From Correlation to Causation
Li, R., Mao, Z., Ye, X., & Zuo, T. (2021) · Microorganisms · doi:10.3390/microorganisms9051017 · Cited by 43
Schubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Min, F., Hu, J., Huang, T., Huang, Y., Nie, S., Xiong, T., & Xie, M. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113662 · Cited by 40
CAR-T Cell Therapy and the Gut Microbiota
Asokan, S., Cullin, N., Stein‐Thoeringer, C. K., & Elinav, E. (2023) · Cancers · doi:10.3390/cancers15030794 · Cited by 42
Mitra, A., Gültekin, M., Ellis, L. B., Bizzarri, N., Bowden, S. J., Taumberger, N., Bracic, T., Vieira‐Baptista, P., Sehouli, J., & Kyrgiou, M. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00257-4 · Cited by 40
Guevara‐Ramírez, P., Cadena-Ullauri, S., Paz‐Cruz, E., Ruiz‐Pozo, V. A., Tamayo‐Trujillo, R., Cabrera‐Andrade, A., & Zambrano, A. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910255 · Cited by 39
Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease
Duan, J., Li, Q., Cheng, Y., Zhu, W., Liu, H., & Li, F. (2024) · MedComm · doi:10.1002/mco2.70017 · Cited by 43
Tomalová, B., Šírová, M., Rossmann, P., Pola, R., Strohalm, J., Chytil, P., Černý, V., Tomala, J., Kabešová, M., Říhová, B., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.023 · Cited by 39
Xiao, D., Ren, W., Bin, P., Chen, S., Yin, J., Gao, W., Liu, G., Nan, Z., Hu, X., & He, J. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.01.009 · Cited by 40
Flórez, A. B., Sierra, M., Ruas‐Madiedo, P., & Mayo, B. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.07.011 · Cited by 39
Shi, J., Geng, C., Sang, M., Gao, W., Li, S., Yang, S., & Zheng, L. (2019) · Oncology Letters · doi:10.3892/ol.2019.10187 · Cited by 43
Gately, S. T. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_10 · Cited by 43
Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria
Aindelis, G., & Chlichlia, K. (2020) · Vaccines · doi:10.3390/vaccines8020329 · Cited by 43
The brain–gut axis in gastrointestinal cancers
Alpert, O., Begun, L., Issac, T., & Solhkhah, R. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2019-gi-04 · Cited by 40
Influence of immunomodulatory drugs on the gut microbiota
Cohen, I., Ruff, W. E., & Longbrake, E. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.009 · Cited by 39
Diefenbach, C., Peters, B. A., Li, H., Raphael, B. G., Moskovits, T., Hymes, K. B., Schlüter, J., Chen, J., Bennani, N. N., Witzig, T. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003129 · Cited by 40
Caballero, A. C., Escribà-García, L., Álvarez‐Fernández, C., & Briones, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904497 · Cited by 41
Yin, B., Wang, X., Fang, Y., Li, Y., & Lu, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.899111 · Cited by 40
Gut microbiota in acute leukemia: Current evidence and future directions
Zhou, Y., Zhou, C., & Zhang, A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1045497 · Cited by 40
Metadata
- Authors
- Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C. O., Doré, J., Kroemer, G., Lepage, P., Boneca, I. G., Ghiringhelli, F., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Agency for Science, Technology and Research (SG)
- Institut National de la Santé et de la Recherche Médicale, U866, Centre Georges François Leclerc, Dijon, France.
- Service de Microbiologie, Institut Gustave Roussy, Villejuif, France.
- Institut Gustave Roussy (FR)
- Institut Pasteur (FR)
- Nimalerie Centrale, Institut Pasteur, Paris, France.
- Institut National de la Recherche Agronomique, Micalis–UMR1319, 78350 Jouy-en-Josas, France.
- Centre National de la Recherche Scientifique (FR)
- Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, Marseille, France.
- Université d'Orléans (FR)
- University of Alabama at Birmingham (US)
- AgroParisTech (FR)
- Corresponding author
- Ghiringhelli, François
- Zitvogel, Laurence
- ORCID
- Mignot, Grégoire
- Yamazaki, Takahiro
- Daillère, Romain
- Hannani, Dalil
- Pfirschke, Christina
- Engblom, Camilla
- Schlitzer, Andreas
- Ginhoux, Florent
- Woerther, Paul-Louis
- Eberl, Gérard
- Clermont, Dominique
- Opolon, Paule
- Ryffel, Bernhard
- Elson, Charles O.
- Kroemer, Guido
- Lepage, Patricia
- Boneca, Ivo Gomperts
- Ghiringhelli, François
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 971-976
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4048947
- OpenAlex
- W2059128083
- Cited by
- 2,050
- References
- 43
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 176 · 2023: 216 · 2022: 234 · 2021: 217 · 2020: 220 · 2019: 183 · 2018: 137 · 2017: 116 · 2016: 98 · 2015: 101 · 2014: 69 · 2013: 6
- FWCI
- 40.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- HAL AMU (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-11-PHUC-0002)
- National Cancer Institute (P50CA086355)
- National Institute of Allergy and Infectious Diseases (R01AI084880)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK071176)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cyclophosphamide, gut microbiota, antitumor immunity, Gram-positive bacteria, Th17 cells, memory T cells, secondary lymphoid organs, bacterial translocation, germ-free mice, antibiotic therapy, adoptive transfer, small intestine
- MeSH terms
- Animals, Anti-Bacterial Agents, Antineoplastic Agents, Cyclophosphamide, Germ-Free Life, Gram-Positive Bacteria, Immunologic Memory, Immunosuppressive Agents, Intestine, Small, Lymphoid Tissue, Neoplasms, Bacterial Translocation, Adoptive Transfer, Mice, Th17 Cells, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.